N-[3-(dimethoxymethylsilyl)-2-methylpropyl]ethylenediamine

Toxicity to reproduction

Administrative data

Endpoint:

extended one-generation reproductive toxicity - basic test design (Cohorts 1A, and 1B without extension)

Data waiving:

study scientifically not necessary / other information available

Justification for data waiving:

the extended one-generation reproductive toxicity study does not need to be conducted because there are no results from available repeated dose toxicity studies that indicate adverse effects on reproductive organs or tissues, or reveal other concerns in relation with reproductive toxicity

Cross-reference

Cross-reference 1

Reason / purpose for cross-reference:

data waiving: supporting information

Reference

Endpoint:

sub-chronic toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

30 Jul 2019 - 04 May 2020

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)

Version / remarks:

25 June 2018

Deviations:

no

GLP compliance:

yes

Limit test:

no

Species:

rat

Strain:

other: Crl:CD(SD)

Details on species / strain selection:

The Sprague Dawley rat was chosen as the animal model for this study as it is an accepted rodent species for nonclinical toxicity testing by regulatory agencies.

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, NC
- Age at study initiation: 7 weeks old
- Weight at study initiation: 166 and 281 g
- Fasting period before study: no; however, Animals did not have access to diet during the conduct of the functional observational battery (FOB) and motor activity (MA) assessments
- Housing: Group housed (2–3 animals of the same sex and same dosing group together) in polycarbonate, solid-bottom cages containing appropriate bedding material
- Diet: PMI Nutrition International , LLC Certified Rodent LabDiet 5002 meal provided ad libitum, except during designated periods of fasting
- Water: Municipal tap water, treated by reverse osmosis and ultraviolet irradiation provided ad libitum
- Acclimation period: at least 7 days

DETAILS OF FOOD AND WATER QUALITY: Results of analysis for nutritional components and environmental contaminants were provided by the supplier and are on file at the Testing Facility. It was considered that there are no known contaminants in the feed at levels that would interfere with the objectives of the study.

Periodic analysis of the water as performed, and results of these analyses are on file at the Testing Facility. It was considered that there are no known contaminants in the water at levels that could interfere with the outcome of the study.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 26
- Humidity (%): 30 to 70
- Air changes (per hr): Ten or more air changes per hour, 100% fresh air
- Photoperiod (hrs dark / hrs light): 12 hours light and 12 hours dark

Route of administration:

oral: gavage

Vehicle:

corn oil

Details on oral exposure:

PREPARATION OF DOSING SOLUTIONS: Dosing formulations of test material were prepared every 4 days or less. Dosing formulations were prepared at appropriate concentrations to meet dose level requirements.

VEHICLE
- Justification for use and choice of vehicle (if other than water): Corn oil was chosen as the appropriate vehicle based on the test substance’s characteristics and the subsequent relevant OECD testing guidelines.
- Concentration in vehicle: undiluted
- Amount of vehicle: The control group was administered 4 mL/kg
- Lot/batch no.: 2IC0148
- Purity: not reported

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

The analyzed dosing formulations contained 101% to 109% of the test substance which was within the protocol-specified range of target concentrations for suspensions (85% to 115%) and were homogeneous.

Duration of treatment / exposure:

90 days

Frequency of treatment:

Daily

Dose / conc.:

30 mg/kg bw/day (actual dose received)

Dose / conc.:

100 mg/kg bw/day (actual dose received)

Dose / conc.:

300 mg/kg bw/day (actual dose received)

No. of animals per sex per dose:

15 males and 15 females in the control and high-dose groups; 10 males and 10 females in the mid- and low-dose groups

Control animals:

yes, concurrent vehicle

Details on study design:

- Dose selection rationale: The target exposure concentrations were selected by the Sponsor Representative in consultation with the Study Director based on a previous repeated-dose study. In that study, the test substance was administered to up to 5 males and females via oral gavage for up to 14 consecutive days at dosage levels of 0, 90, 180, 300, and 500 mg/kg bw/day. Based on decreased body weights, dosage levels of 30, 100, and 300 mg/kg bw/day were selected for this study.
- Rationale for animal assignment: Animals were assigned to groups by a stratified randomization scheme designed to achieve similar group mean body weights. Males and females were randomized separately.
- Fasting period before blood sampling for clinical biochemistry: yes; at least 8 hours (no more than 24 hours)

Positive control:

None

Observations and examinations performed and frequency:

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Mortality was observed at least twice daily (morning and afternoon), beginning upon arrival through termination/release. Cageside observations were made at least once daily on non-dosing/recovery days.
- Cage side observations checked in tables 1 though 5

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Detailed clinical observations were made on Day 1 (prior to dosing) and then weekly (± 2 days) during the study period, and on the day of scheduled necropsy (animals selected for necropsy).

BODY WEIGHT: Yes
- Time schedule for examinations: Individual body weights were recorded on Day 1 (prior to dosing), weekly (± 2 days) during the study period, on the day prior to the first day of scheduled necropsies, and on the day of the scheduled necropsy.

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes

OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Near the end of the dosing period (Day 85)
- Dose groups that were examined: All Main and Recovery Study animals

HAEMATOLOGY: Yes
- Time schedule for collection of blood: On the day of scheduled necropsy (animals scheduled for necropsy)
- Anaesthetic used for blood collection: Yes; euthanized via carbon dioxide inhalation
- Animals fasted: Yes; at least 8 hours (no more than 24 hours)
- How many animals: Groups 1–4 (Main and Recovery Study animals)
- Parameters checked in table 6 and 7 were examined.

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: On the day of scheduled necropsy (animals scheduled for necropsy)
- Animals fasted: Yes; at least 8 hours (no more than 24 hours)
- How many animals: Groups 1–4 (Main and Recovery Study animals)
- Parameters checked in table 8 were examined.

URINALYSIS: Yes
- Time schedule for collection of urine: On the day of scheduled necropsy (animals scheduled for necropsy)
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes; at least 8 hours (no more than 24 hours)
- Parameters checked in table 9 were examined.

NEUROBEHAVIOURAL EXAMINATION: No

IMMUNOLOGY: No

OTHER: Yes; Functional Observational Battery (FOB); T3, T4, TSH hormones were analyzed, as well as estrous cycle

Sacrifice and pathology:

GROSS PATHOLOGY: Yes (see tables 10 and 11); Animals euthanized for humane reasons or at study termination were euthanized by carbon dioxide inhalation, followed by exsanguination. Main and Recovery Study animals were subjected to a complete necropsy examination, which included evaluation of the carcass; all external surfaces and orifices; the cranial cavity and external surfaces of the brain; and thoracic, abdominal, and pelvic cavities with their associated organs and tissues.

The organs identified in Table 11 were weighed at necropsy for all scheduled euthanasia animals. Organ weights were not recorded for animals found dead or euthanized in poor condition or in extremis. Paired organs were weighed together. Organ to body weight ratio (using the terminal body weight) and organ to brain weight ratios were calculated.

HISTOPATHOLOGY: Yes (see tables 10 and 12); Tissues identified in Table 12 (except animal identification and bone marrow smears) from animals found dead, euthanized in extremis, and in the control and high-dose groups at the terminal necropsy were embedded in paraffin, sectioned, mounted on glass slides, and stained with hematoxylin and eosin. In addition, gross lesions and the testes were prepared from all animals in the low- and mid-dose groups at the terminal necropsy and all animals at the recovery necropsy

Other examinations:

For the functional observational battery tests, animals (all main Ssudy and recovery animals) were evaluted during the final week of test substance administration and near the end of the recovery period. Animals were evaluted for sensory activity, neuromuscular observations, and motor activity.

For the thyroid hormone analysis, sample were collected on on the days of scheduled necropsy. For total T3 and T4 analysis, hormone samples were analyzed using a validated UHPLC/MS/MS assay. For TSH analysis, hormone samples were analyzed using a qualified radioimmunoassay procedure.

Estrous cycle was evaluted on the day of scheduled necropsy for all main and recovery study animals. To determine estrous cycle, vaginal lavages were performed to prepare vaginal smears; from the smears, Giemsa stained slides were prepared from all females and read.

Statistics:

Body weight, body weight gains, food consumption, hematology variables, coagulation variables, clinical chemistyr variables, urinalysis variables, organ weights, and organ weights relative to body and brain weight were analysed through a parametric/non-parametric analysis. For the parametric/non-parametric analysis, Levene’s test as used to assess the homogeneity of group variances.

The groups were compared using an overall one-way ANOVA F-test if Levene’s test was not significant or the Kruskal-Wallis test if it was significant. If the overall F-test or Kruskal-Wallis test was found to be significant, then pairwise comparisons were conducted using Dunnett’s or Dunn’s test, respectively.

Clinical signs:

effects observed, non-treatment-related

Description (incidence and severity):

There were no adverse test substance-related clinical observations.
However, several males and females in the 300 mg/kg bw/day group and a single male and female in the 100 mg/kg bw/day group were noted with abnormal breathing sounds over the course of the study. Due to the properties of the test substance/formulation (likely irritant, viscous nature), these findings were considered to be related to administration, rather than a systemic effect of the test substance. Two males in the 300 mg/kg bw/day group were still noted with these findings throughout the recovery period, although it was not observed during the functional observational battery evaluations during Week 16.

Additionally, several males and females in the 100 and 300 mg/kg/day group were noted with wet fur around the mouth. This also was considered to be a response to being dosed with a viscous formulation, rather than a systemic effect of the test substance.

All other clinical observations in the test substance-treated groups were noted with similar incidence in the control group, were limited to single animals, were not noted in a dose-related manner, and/or were common findings for laboratory rats of this age and strain.

Mortality:

mortality observed, non-treatment-related

Description (incidence):

There were no clear test substance-related deaths.

Six unscheduled deaths occurred in the 300 mg/kg bw/day group males and females during the dosing period. Five of the unscheduled deaths (Animal Nos. 4001, 4002, 4008, 4512, and 4513) were attributed to laryngeal and/or tracheal neutrophilic inflammation and were consistent with gavage-associated reflux. The cause of the unscheduled death of Animal No. 4509 was undetermined and a relationship to the test substance was uncertain. However, given limited sampling of the larynx/trachea, clinical observations of gasping, and gross observations of gas filled tissues (suggestive of respiratory distress), gavage-associated reflux could not be excluded for this animal also.In addition, clinical observations noted in these animals prior to death included abnormal breathing sounds, suspected dehydration, labored breathing, abdominal distention, thin, ungroomed fur, wet fur around mouth, muzzle, and/or urogenital area, ventral cervical area, red staining of fur on muzzle and/or periorbital area, and/or yellow fur stating on thoracic and/or urogenital area; body weight losses were noted in a single male (No. 4002; 5.5%) and all females (7.9% to 22.0%) for the interval prior to death.

Body weight and weight changes:

effects observed, treatment-related

Description (incidence and severity):

Test substance-related lower body weights were noted in the 300 mg/kg bw/day group males.

Test substance-related lower mean body weight gains were noted in the 300 mg/kg bw/day group males throughout the dosing period when compared to the control group, which resulted in 7.1% lower mean body weight at the end of the dosing period. Higher mean body weight gains were noted in the 300 mg/kg/day group males throughout the recovery period (statistically significant for the first 2 weeks of the recovery period) when compared to the control group, which resulted in 1.0% lower mean body weight at the end of the recovery period. These higher body weight gains reduced the difference in mean body weights between the end of the dosing and recovery periods in the 300 mg/kg bw/day group males from 7.1% to 1.0%, respectively, when compared to the control group.

There were no other test substance-related effects on body weight in males and no test substance related effects in females. However, some statistically significant differences were observed when the control and test substance-treated groups were compared. These were not considered test substance-related and were instead attributed to normal variation.

Food consumption and compound intake (if feeding study):

effects observed, non-treatment-related

Description (incidence and severity):

There was no test substance-effects on food consumption during the dosing phase of the study. However, some statistically significant differences were observed when the control and test substance-treated groups were compared. These were not considered test substance-related and were instead attributed to normal variation.

During the recovery period, the 300 mg/kg/day group males had higher mean food consumption throughout the recovery period when compared to the control group.

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

no effects observed

Haematological findings:

effects observed, treatment-related

Description (incidence and severity):

NEED TO ENTER AFTER REPORT IS FINALIZED; EDITS REQUESTED IN DRAFT UNDER COAGULATION

Hematology parameters were unaffected by test substance administration. However, some statistically significant differences were observed when the control and test substance-treated groups were compared; however, differences were not considered test substance-related and were instead attributed to normal biological variation.

Test substance-related changes in coagulation parameters on Days 91/92 were limited to lower fibrinogen in the 300 mg/kg bw/day group females. Additionally, test substance-related changes in clinical chemistry parameters on Day 91/92 included higher alanine aminotransferase in the 300 mg/kg bw/day group males and females and lower cholesterol, high density lipoprotein, and low density lipoprotein in the 300 mg/kg bw/day group females. There were no other test substance-related changes in clinical pathology parameters at the terminal necropsy or at the recovery necropsy.

Clinical biochemistry findings:

effects observed, treatment-related

Description (incidence and severity):

Test substance-related changes in clinical chemistry parameters were noted in the 300 mg/kg bw/day group males and females.

Test substance-related minimally increased mean alanine aminotransferase (ALT) was noted in the 300 mg/kg bw/day group males and females on Day 91/92 when compared to control group. It was noted that in females, the mean for the concurrent control was artificially elevated by an outlier (Female No. 1507). When this outlier value was removed, the mean ALT was changed from 104.7 U/L to 57 U/L. Compared to the adjusted mean control group female value, the 300 mg/kg bw/day group females were considered to be elevated. Additionally, test substance-related lower mean cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were noted in the 300 mg/kg bw/day group females when compared to the control group. There were no correlating test substance-related microscopic changes in the liver at the primary necropsy. There were no test substance-related changes in ALT, cholesterol, HDL, or LDL noted at the recovery necropsy. Accordingly, the noted clinical chemistry effects were not considered adverse. Remaining differences in clinical chemistry parameters, regardless of statistical significance, were not considered not test substance-related based on their absence of a dose response, general overlap of individual values with the range of control values, and/or were of a magnitude of change commonly observed in rats under similar study conditions.

Urinalysis findings:

effects observed, non-treatment-related

Description (incidence and severity):

Statistically significant differences when the test substance treated males and females were compared to the control group at the Week 16 evaluations were limited to higher mean urination in the 300 mg/kg bw/day group males and lower mean rearing in the 300 mg/kg bw/day group females at Week 16; however, these differences were not considered test substance-related because they were consistent with Charles River Ashland historical data.

No other urinalysis findings were noted in the study report.

Behaviour (functional findings):

effects observed, treatment-related

Description (incidence and severity):

Home cage observations, open field observations, sensory and neuromuscular observations were unaffected by test substance administration.
Test substance-related lower total and ambulatory motor activity counts were noted in the 300 mg/kg bw/day group females. In females, statistically significant lower mean total and ambulatory activity counts were noted at the Week 13 evaluation in the 300 mg/kg bw/day group. The largest difference between the control and 300 mg/kg bw/day groups was noted during the first 10 minutes. The activity curves in the 300 mg/kg bw/day group females were lower throughout the testing period and were essentially parallel to the concurrent control group. Because statistical significance was only noted in the 300 mg/kg bw/day group females for both total and ambulatory activity, this was considered to be test substance-related effect. Mean counts for both total and ambulatory activity were within the range of means in the Charles River Ashland historical control data. Based on the lack of further observations in the functional observational battery and/or during routine examinations, lower mean total and ambulatory activity counts were not considered adverse. There were no effects on total and ambulatory activity at the Week 16 recovery assessment on females compared to the control group. Motor activity patterns (total and ambulatory activity counts) in males were unaffected by test substance administration.

Immunological findings:

not examined

Organ weight findings including organ / body weight ratios:

effects observed, non-treatment-related

Description (incidence and severity):

No test substance-related organ weight changes were noted at the terminal euthanasia. There were isolated organ weight values that were statistically different from their respective controls. There were, however, no patterns, trends, or correlating data to suggest these values were toxicologically relevant. Thus, the organ weight differences observed were considered incidental and/or related to difference of sexual maturity and unrelated to administration of the test substance.

Gross pathological findings:

no effects observed

Neuropathological findings:

not examined

Histopathological findings: non-neoplastic:

no effects observed

Histopathological findings: neoplastic:

not examined

Other effects:

no effects observed

Description (incidence and severity):

T3, T4, and TSH were unaffected by test substance administration. Any differences, including those that reached statistical significance, were not considered test substance-related based on their absence of a dose response, and/or general overlap of individual values with the range of control values.

The number of females in estrus, diestrus, or proestrus were comparable between the control and test substance-treated groups at the terminal and recovery euthanasia.

Key result

Dose descriptor:

NOAEL

Effect level:

300 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: no definitive test substance-related unscheduled deaths or findings that were considered adverse

Key result

Critical effects observed:

no

Conclusions:

In an oral gavage study conducted in accordance with OECD 408 and GLP the NOAEL for N [3 (dimethoxymethylsilyl)-2-methylpropyl]ethylenediamine (CAS 23410-40-4) was considered to be 300 mg/kg bw/day based on the lack of definitive test substance-related unscheduled deaths or findings that were considered adverse.

Cross-reference 2

Reason / purpose for cross-reference:

data waiving: supporting information

Reference

Endpoint:

developmental toxicity

Type of information:

experimental study

Adequacy of study:

key study

Study period:

30 Aug 2019 to 30 Jan 2020

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 414 (Prenatal Developmental Toxicity Study)

Version / remarks:

June 2018

GLP compliance:

yes

Limit test:

no

Species:

rat

Strain:

other: Crl:CD(SD)

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, NC
- Age at study initiation: 11 - 12 weeks old
- Weight at study initiation: between 200 and 250 g
- Fasting period before study: not reported
- Housing: individually housed in solid-bottom cages containing appropriate bedding equipped with an automatic watering valve.
- Diet: PMI Nutrition International, LLC Certified Rodent LabDiet® 5002 (meal) was provided ad libitum
- Water: Municipal tap water after treatment by reverse osmosis was freely available to each animal via an automatic watering system.
- Acclimation period: prior to the initiation of dosing.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 26
- Humidity (%): 30 - 70
- Air changes (per hr): 10 or more
- Photoperiod (hrs dark / hrs light): 12-hr light/12-hr dark

Route of administration:

oral: gavage

Vehicle:

corn oil

Details on exposure:

PREPARATION OF DOSING SOLUTIONS: The dosing formulations were prepared every 4 days and an adequate amount of each formulation was dispensed into daily aliquots, which were stored at room temperature, protected from light, under nitrogen, until use.

VEHICLE
- Lot/batch no. (if required): 2IC0148

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

The analyzed dosing formulations contained 107% to 114% of the test substance which was within the protocol-specified range of target concentrations for suspensions (85% to 115%) and were homogeneous.

Details on mating procedure:

- Impregnation procedure: purchased timed pregnant

Duration of treatment / exposure:

single daily oral gavage dose during Gestation Days 6 through 20

Frequency of treatment:

single daily dose

Duration of test:

from Gestation Days 6 through 20

Dose / conc.:

50 mg/kg bw/day (actual dose received)

Dose / conc.:

150 mg/kg bw/day (actual dose received)

Dose / conc.:

400 mg/kg bw/day (actual dose received)

No. of animals per sex per dose:

25 dams/dose

Control animals:

yes, concurrent vehicle

Details on study design:

- Dose selection rationale: Doses were based on a dose range-finding study, in which 5 males and 5 females (non-pregnant) Sprague Dawley rats per dose group via oral gavage for up to 14 consecutive days at dosage levels of 0, 90, 180, 300, and 500 mg/kg bw/day. At 500 mg/kg/day, the test substance caused moribundity, leading to unscheduled euthanasia, and thus exceeds a maximum tolerated dose. Therefore, the dose levels selected for this study were 0, 50, 150, and 400 mg/kg bw/day.
- Rationale for animal assignment: Animals were assigned to groups by a stratified randomization scheme designed to achieve similar group mean body weights. Animals in poor health or at extremes of body weight range were not assigned to groups.

Maternal examinations:

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily, once in the morning and once in the afternoon.
- Cage side observations included, but were not limited to: labored breathing, fur staining, thinning fur, abnormal gait, decreased activity, and increased salivation.

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once daily, beginning on the day of receipt and lasting through euthanasia

BODY WEIGHT: Yes
- Time schedule for examinations: individually on Gestation Days 0 (by supplier) and 5 - 21 (daily)

FOOD CONSUMPTION AND COMPOUND INTAKE: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No

WATER CONSUMPTION AND COMPOUND INTAKE: No

POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 21
- Organs examined: liver and kidneys

OTHER: Blood samples for thyroid hormone analyses were collected (prior to noon in order to avoid diurnal fluctuations in thyroid hormone levels) via a jugular vein into tubes without anticoagulant

Ovaries and uterine content:

The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: Placentae were also examined

Fetal examinations:

- External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: Yes: half per litter

Statistics:

All statistical tests were conducted at the 5% significance level. All pairwise comparisons were conducted using two sided tests and are reported at the 1% and 5% levels.

Body weight; body weight gain; food consumption; gravid uterine weight and corrected maternal body weights; litter means; organ weights; and anogenital distance: Levene's test was used to assess the homogeneity of group variances. The groups were compared using an overall one-way ANOVA F-test if Levene's test was not significant or the Kruskal-Wallis test if it was significant. If the overall F-test or Kruskal-Wallis test was found to be significant, then pairwise comparisons were conducted using Dunnett's or Dunn's test, respectively.

Ovarian and uterine content; litter % of fetuses with external/visceral/skeletal abnormalities: The groups were compared using an overall Kruskal-Wallis test. If the overall Kruskal-Wallis test was found to be significant, then the above pairwise comparison was conducted using Dunn's test.

Parental indices and mortality; macroscopic findings; microscopic findings: A Fisher’s Exact Test was used to conduct pairwise group comparisons of interest.

Thyroid hormone analysis: The groups were compared using an overall one-way ANOVA F-test. If the overall F-test is found to be significant, then pairwise comparisons will be conducted using Dunnett's test.

Indices:

Postimplantation Loss/Litter = (No. Dead Fetuses, Resorptions (Early or Late) per Group) / (No. Gravid Females per Group) X 100
Summation Per Group (%) = (Sum of Postimplantation Loss per Litter) / (No. Litters per Group) X 100
Postimplantation Loss/Litter (%) = (No. Dead Fetuses, Resorptions (Early or Late) per Group) / (No. Implantation Sites per Litter) X 100

Historical control data:

Charles River Ashland has historical data on the background incidence of fetal malformations and developmental variations in the Crl:CD(SD) rat.

Clinical signs:

effects observed, treatment-related

Description (incidence and severity):

Labored breathing and/or abnormal breathing sounds were noted for 17 of 25 females in the 400 mg/kg bw/day group at the daily examinations and/or 1 - 2 hours following dose administration generally throughout the study (Gestation Days 8 - 21). Abnormal breathing sounds were also noted for 8 of 25 females in the 150 mg/kg bw/day group during Gestation Days 7 - 19, albeit to a lesser extent than noted in the 400 mg/kg bw/day group.

Dermal irritation (if dermal study):

not examined

Mortality:

mortality observed, non-treatment-related

Description (incidence):

One female in the 150 mg/kg bw/day group was found dead on gestation day 18. No clinical observations or noteworthy changes in body weight were noted for this female prior to death, and no macroscopic findings were observed at necropsy. In the absence of unscheduled deaths in the high-dose group, this mortality was not considered test substance-related.

Body weight and weight changes:

effects observed, non-treatment-related

Description (incidence and severity):

Mean maternal body weights, body weight gains, corrected body weights, corrected body weight gains, and gravid uterine weights in the 50, 150, and 400 mg/kg bw/day groups were unaffected by test substance administration. Differences from the control group were slight and not statistically significant, with the following exceptions. A statistically significantly higher mean body weight gain during Gestation Days 6 - 7 and lower mean body weight gain during Gestation Days 20 - 21 were noted in the 400 mg/kg bw/day group compared to the control group. Because these body weight changes failed to produce a noteworthy effect on the overall body weight gain and absolute mean body weights in this group, they were considered transient and unrelated to test substance administration.

Food consumption and compound intake (if feeding study):

effects observed, non-treatment-related

Description (incidence and severity):

Mean maternal food consumption, evaluated as g/animal/day and g/kg/day, in the 50, 150, and 400 mg/kg bw/day groups was unaffected by test substance administration. Differences from the control group were slight and not statistically significant.

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

not examined

Haematological findings:

not examined

Clinical biochemistry findings:

not examined

Urinalysis findings:

not examined

Behaviour (functional findings):

not examined

Immunological findings:

not examined

Organ weight findings including organ / body weight ratios:

no effects observed

Gross pathological findings:

no effects observed

Neuropathological findings:

not examined

Histopathological findings: non-neoplastic:

no effects observed

Histopathological findings: neoplastic:

not examined

Other effects:

effects observed, non-treatment-related

Description (incidence and severity):

No test substance-related effects on mean TSH, T3, or T4 concentrations were noted at any dose level. Mean TSH concentration in the 400 mg/kg bw/day group females was 21.8% lower than the control group. This decrease was not considered test substance-related because the difference from the control group was not statistically significant, and there were no effects on thyroid gland weight or histopathology in the thyroid at this dose level.

Number of abortions:

no effects observed

Pre- and post-implantation loss:

no effects observed

Total litter losses by resorption:

no effects observed

Early or late resorptions:

no effects observed

Dead fetuses:

no effects observed

Changes in pregnancy duration:

no effects observed

Changes in number of pregnant:

no effects observed

Other effects:

not specified

Details on maternal toxic effects:

Intrauterine growth and survival were unaffected by test substance administration at dose levels of 50, 150, and 400 mg/kg bw/day. Parameters evaluated included mean litter proportions of postimplantation loss, mean number of viable/live fetuses, mean fetal body weights, and fetal sex ratios. Differences from the control group were slight, not statistically significant, and/or did not occur in a dose-related manner.

Mean numbers of corpora lutea and implantation sites and the mean litter proportions of pre-implantation loss were similar across all groups.

Key result

Dose descriptor:

NOAEL

Effect level:

400 mg/kg bw/day (actual dose received)

Based on:

test mat.

Basis for effect level:

other: No adverse effects observed

Key result

Abnormalities:

effects observed, non-treatment-related

Fetal body weight changes:

no effects observed

Reduction in number of live offspring:

no effects observed

Changes in sex ratio:

no effects observed

Changes in litter size and weights:

no effects observed

Changes in postnatal survival:

no effects observed

External malformations:

no effects observed

Skeletal malformations:

effects observed, non-treatment-related

Description (incidence and severity):

No test substance-related skeletal malformations were observed in fetuses in this study. Two fetuses in the 150 mg/kg bw/day group each had an absent lumbar vertebra. This finding was not considered test substance-related because no skeletal malformations were noted in the high-dose group. No other skeletal malformations were noted in this study.

Visceral malformations:

effects observed, non-treatment-related

Description (incidence and severity):

No test substance-related visceral malformations were observed in fetuses in this study. One fetus in the 50 mg/kg bw/day group had a retroesophageal right subclavian artery; however, this finding was not observed in a dose-related manner, and therefore was not considered test substance-related. No other visceral malformations were noted in this study.

Other effects:

no effects observed

Description (incidence and severity):

Mean anogenital distance (absolute and relative to cube root of body weight) was unaffected by test substance administration at all dose levels. Differences from the control group were slight and not statistically significant.

Details on embryotoxic / teratogenic effects:

Mean mean number of viable/live fetuses, mean fetal body weights, and fetal sex ratios were unaffected by treatment. Mean anogenital distance (absolute and relative to cube root of body weight) was unaffected by test substance administration at all dose levels. No test substance-related skeletal or visceral malformations were observed in fetuses in this study.

Key result

Dose descriptor:

NOAEL

Effect level:

400 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: No adverse effects observed

Key result

Abnormalities:

effects observed, non-treatment-related

Key result

Developmental effects observed:

no

Conclusions:

In an oral gavage developmental study conducted in accordance to OECD 414 and to GLP, the NOAEL for N-[3-(dimethoxymethylsilyl)-2-methylpropyl]ethylenediamine for maternal toxicity and embryo/fetal development was 400 mg/kg bw/day, as no significant adverse effects were observed up to the highest dose of 400 mg/kg bw/day tested in rats.